CONCORDBIO1,445.20

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹15,119 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue-12.1+1.8
EBITDA-27.4-7.7
Net Income-30.2-8.3
EPS (adj.)-29.8-8.0
Total Assets+9.9+14.6
Total Equity+11.2+14.9
Free Cash Flow+28.8-2.3
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.